Market closedNon-fractional
Jazz Pharmaceuticals/JAZZ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Ticker
JAZZ
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Dublin, Ireland
Employees
2,800
Website
www.jazzpharma.com
JAZZ Metrics
BasicAdvanced
$6.9B
Market cap
21.74
P/E ratio
$5.04
EPS
0.62
Beta
-
Dividend rate
Price and volume
Market cap
$6.9B
Beta
0.62
Financial strength
Current ratio
2.266
Quick ratio
1.62
Long term debt to equity
139.627
Total debt to equity
156.004
Interest coverage (TTM)
2.10%
Management effectiveness
Return on assets (TTM)
4.07%
Return on equity (TTM)
9.41%
Valuation
Price to earnings (TTM)
21.744
Price to revenue (TTM)
1.797
Price to book
1.87
Price to tangible book (TTM)
-2.11
Price to free cash flow (TTM)
6.937
Growth
Revenue change (TTM)
2.81%
Earnings per share change (TTM)
-302.92%
3-year revenue growth (CAGR)
16.41%
3-year earnings per share growth (CAGR)
-17.81%
What the Analysts think about JAZZ
Analyst Ratings
Majority rating from 18 analysts.
JAZZ Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$902M
-10.87%
Net income
-$15M
-115.52%
Profit margin
-1.61%
-117.33%
JAZZ Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$4.51
$4.84
$5.02
$2.68
-
Expected
$4.43
$4.93
$5.18
$4.18
$4.74
Surprise
1.76%
-1.87%
-3.17%
-35.88%
-
JAZZ News
AllArticlesVideos
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting
PRNewsWire·1 day ago
Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
PRNewsWire·5 days ago
Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
PRNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Jazz Pharmaceuticals stock?
Jazz Pharmaceuticals (JAZZ) has a market cap of $6.9B as of July 26, 2024.
What is the P/E ratio for Jazz Pharmaceuticals stock?
The price to earnings (P/E) ratio for Jazz Pharmaceuticals (JAZZ) stock is 21.74 as of July 26, 2024.
Does Jazz Pharmaceuticals stock pay dividends?
No, Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Jazz Pharmaceuticals dividend payment date?
Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders.
What is the beta indicator for Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Jazz Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.